SNGX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.80%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Soligenix Insider Trading History Chart

Soligenix Share Price & Price History

^$2.23

▲ +0.02 (0.90%)

As of 04/2/2025 03:36 PM ET

Days: 30 | 90 | 365

Soligenix Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/18/2022	Christopher J. Schaber	CEO	Buy	1,250	$7.04	$8,800.00	5,630
5/18/2022	Richard Straube	CMO	Buy	500	$8.00	$4,000.00	500

SEC Filings (Institutional Ownership Changes) for Soligenix (NASDAQ:SNGX)

3.60% of Soligenix stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Soligenix Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/12/2025	Geode Capital Management LLC	26,094	$71K	0.0%	+42.1%	1.040%
10/28/2024	Stephens Inc. AR	46,262	$0.18M	0.0%	N/A	4.687%
8/15/2024	Armistice Capital LLC	80,000	$0.21M	0.0%	N/A	8.105%
7/11/2024	OLD National Bancorp IN	10,000	$26K	0.0%	N/A	1.010%
11/15/2023	Sabby Management LLC	740,564	$0.41M	0.3%	-9.0%	9.120%
8/14/2023	Anson Funds Management LP	514,144	$0.36M	0.1%	N/A	6.332%
5/16/2023	First Wilshire Securities Management Inc.	23,334	$46K	0.0%	-93.3%	0.784%
4/27/2022	ARGI Investment Services LLC	46,836	$34K	0.0%	+127.6%	0.109%
2/14/2022	Knoll Capital Management LLC	436,580	$0.29M	0.2%	-44.6%	1.089%
11/16/2021	Two Sigma Securities LLC	58,791	$62K	0.0%	N/A	0.147%
11/9/2021	BlackRock Inc.	115,694	$0.12M	0.0%	-11.4%	0.289%
9/17/2021	Virtu Financial LLC	80,665	$90K	0.0%	-37.0%	0.201%
8/16/2021	State Street Corp	44,870	$50K	0.0%	N/A	0.112%
8/13/2021	Renaissance Technologies LLC	296,111	$0.33M	0.0%	N/A	0.739%
8/13/2021	Geode Capital Management LLC	244,085	$0.27M	0.0%	+11.7%	0.609%
8/13/2021	Vanguard Group Inc.	1,647,296	$1.83M	0.0%	+56.8%	4.110%
5/21/2021	Citadel Advisors LLC	85,286	$0.13M	0.0%	N/A	0.213%
5/19/2021	Virtu Financial LLC	128,066	$0.20M	0.0%	+190.4%	0.320%
5/18/2021	Citadel Advisors LLC	85,286	$0.13M	0.0%	N/A	0.213%
5/12/2021	Geode Capital Management LLC	218,536	$0.33M	0.0%	+70.2%	0.546%
5/10/2021	GSA Capital Partners LLP	136,502	$0.21M	0.0%	+15.0%	0.341%
5/7/2021	BlackRock Inc.	114,667	$0.18M	0.0%	+20.0%	0.287%
5/4/2021	Savant Capital LLC	22,300	$34K	0.0%	+48.7%	0.056%
4/15/2021	Dock Street Asset Management Inc.	27,500	$42K	0.0%	N/A	0.069%
2/9/2021	Bank of New York Mellon Corp	28,469	$36K	0.0%	N/A	0.090%
2/5/2021	BlackRock Inc.	95,520	$0.12M	0.0%	+22.8%	0.303%

Data available starting January 2016

See Full Table

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $2.23

$2.17

$2.23

50 Day Range

MA: $2.34

$2.15

$2.56

52 Week Range

Now: $2.23

$1.83

$14.92

Volume

10,067 shs

Average Volume

781,793 shs

Market Capitalization

$5.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.03